Expertise in
3
conditions

Yoshifumi Kawano

Kagoshima, JP 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
3
conditions
Kagoshima, JP 

Overview

Yoshifumi Kawano practices practicing medicine in Kagoshima, Japan.

Kawano is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Blau Syndrome, Acute Lymphoblastic Leukemia (ALL), Juvenile Idiopathic Arthritis (JIA), Bone Marrow Transplant, and Bone Marrow Aspiration.

They are actively involved in clinical research, co-authoring 123 peer reviewed articles and participating in 4 clinical trials.

Locations

Kagoshima, 8908520, Japan
Other Locations
Ube, 7558505, Japan
Kirishima, Japan
Tokyo, Japan
Chiba, Japan
Naka, 3110193, Japan
Omuta, Japan
Kobe, Japan
Yufu, 8795593, Japan
Sapporo, Japan
Oita, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Combination product
Study Drug: Belimumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 2 Less Clinical Trial

123 Total Publications

Breath-hold diffusion-weighted MR imaging (DWI) using deep learning reconstruction: Comparison with navigator triggered DWI in patients with malignant liver tumors.
Breath-hold diffusion-weighted MR imaging (DWI) using deep learning reconstruction: Comparison with navigator triggered DWI in patients with malignant liver tumors.
Journal: Radiography (London, England : 1995)
Published: August 16, 2024

Frequently Asked Questions about Yoshifumi Kawano

Is Yoshifumi Kawano a top-rated expert for Blau Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Yoshifumi Kawano is classified as an Advanced expert for Blau Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yoshifumi Kawano participate in research or clinical trials?

Yes. Yoshifumi Kawano has published 123 articles and abstracts on conditions like Blau Syndrome. You can view a list of Yoshifumi Kawano's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kawano's expertise for a condition
ConditionClose
      View All 69 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile